Outcomes of selexipag for treatment of pulmonary arterial hypertension in an Asian population

被引：1
作者：
Loo, Germaine [1 ]
Yap, Jonathan [1 ,2 ,4 ]
Hon, Jin Shing [1 ]
Ismail, Aidila [1 ]
Ruan, Wen
Low, Andrea [3 ]
Lim, Soo Teik
Tan, Ju Le
机构：
[1] Natl Heart Ctr Singapore, Dept Cardiol, Singapore, Singapore
[2] Duke NUS Med Sch, Singapore, Singapore
[3] Singapore Gen Hosp, Dept Rheumatol & Immunol, Singapore, Singapore
[4] Natl Heart Ctr Singapore, 5 Hosp Dr, Singapore 169609, Singapore
来源：
ANNALS ACADEMY OF MEDICINE SINGAPORE | 2023年 / 52卷 / 04期
关键词：
D O I：
10.47102/annals-acadmedsg.2022474
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：219 / 221
页数：3
相关论文
共 50 条
  • [41] Early Addition of Selexipag to Double Therapy for Pulmonary Arterial Hypertension
    Burger, Charles D.
    Tang, Wenze
    Tsang, Yuen
    Panjabi, Sumeet
    JAMA NETWORK OPEN, 2024, 7 (09) : e2434691
  • [42] TRANSITION OF IV TREPROSTINIL TO ORAL SELEXIPAG IN PULMONARY ARTERIAL HYPERTENSION
    Mahoney, Roshan
    Sweidan, Alexander
    Yaghmour, Bassam
    CHEST, 2021, 160 (04) : 2229A - 2229A
  • [43] Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy
    Hansmann, Georg
    Meinel, Katharina
    Bukova, Mila
    Chouvarine, Philippe
    Wahlander, Hakan
    Koestenberger, Martin
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (07) : 695 - 706
  • [44] Early experience with selexipag for the treatment of adults with pulmonary arterial hypertension associated with congenital heart disease
    Van Dissel, A.
    Post, M.
    Sieswerda, G. T.
    Vliegen, H. W.
    Van Dijk, A. P. J.
    Duijnhouwer, A. L.
    Mulder, B. J. M.
    Bouma, B. J.
    EUROPEAN HEART JOURNAL, 2020, 41 : 2191 - 2191
  • [45] INDIRECT TREATMENT COMPARISON AND COSTMINIMIZATION ANALYSIS OF RIOCIGUAT VERSUS SELEXIPAG IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
    Ornstova, E.
    Tuzil, J.
    Chadimova, K.
    Mlcoch, T.
    Dolezal, T.
    VALUE IN HEALTH, 2022, 25 (12) : S111 - S111
  • [46] Selexipag for the Treatment of Pediatric Pulmonary Hypertension: A Systematic Review
    Li, Meng
    Liu, Lin
    Liu, Cong
    Chen, Zebin
    Li, Weibin
    Li, Xuejuan
    Ma, Xiaopeng
    Zhang, Yumao
    CLINICAL THERAPEUTICS, 2024, 46 (01) : 59 - 68
  • [47] Impact of different sequential triple oral combination therapies based selexipag on outcomes in pulmonary arterial hypertension
    Hu, Xiaoyi
    Yuan, Ping
    Chen, Jun
    Wang, Shang
    Zhao, Hui
    Wei, Yaqin
    Fu, Jiaqi
    Chen, Fadong
    Ruan, Hongyun
    Zhang, Wei
    Zhou, Yanli
    Wang, Qiqi
    Xu, Xiaoling
    Feng, Kefu
    Guo, Jianzhou
    Gong, Sugang
    Zhang, Ruifeng
    Zhao, Qinhua
    Wang, Lan
    CLINICAL CARDIOLOGY, 2024, 47 (02)
  • [48] Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
    Oriaku, Ifeoma
    Patel, Amol
    Safdar, Zeenat
    PULMONARY CIRCULATION, 2020, 10 (01)
  • [49] DEVELOPMENT OF SERONEGATIVE HYPERTHYROIDISM IN A PEDIATRIC PATIENT ON SELEXIPAG FOR PULMONARY ARTERIAL HYPERTENSION
    Rubio, Dalhila Solorzano
    Canter, Ryan
    Hamaker, Mark
    Murray, Mary
    Jelley, Hannah
    HORMONE RESEARCH IN PAEDIATRICS, 2024, 97 : 130 - 131
  • [50] Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension
    Parikh, Kishan S.
    Doerfler, Sean
    Shelburne, Nicholas
    Kennedy, Karla
    Whitson, Jordan
    Dahhan, Talal
    Fortin, Terry
    Rajagopal, Sudarshan
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2020, 75 (04) : 299 - 304
12345